Insider · CIK 0001914503

Easom Eric

Reports to the SEC for 1 company · MENLO PARK, CA

sec.gov

Transactions

Companies

Filings

CIK

0001914503

Forms 4 and 5

Insider transactions

43 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-03-19	ANTXAN2 Therapeutics, Inc. · Stock Option (right to buy)A Award	Director, Chief Executive Officer	AAward	+250K sh	—	—	249,999
2026-03-19	ANTXAN2 Therapeutics, Inc. · Stock Option (right to buy)D Disposition to Issuer	Director, Chief Executive Officer	DDisposition to Issuer	−250K sh	—	—	0
2026-03-19	ANTXAN2 Therapeutics, Inc. · Stock Option (right to buy)A Award	Director, Chief Executive Officer	AAward	+225K sh	—	—	225,000
2026-03-19	ANTXAN2 Therapeutics, Inc. · Stock Option (right to buy)D Disposition to Issuer	Director, Chief Executive Officer	DDisposition to Issuer	−225K sh	—	—	0
2026-03-19	ANTXAN2 Therapeutics, Inc. · Stock Option (right to buy)A Award	Director, Chief Executive Officer	AAward	+268K sh	—	—	267,650
2026-03-19	ANTXAN2 Therapeutics, Inc. · Stock Option (right to buy)D Disposition to Issuer	Director, Chief Executive Officer	DDisposition to Issuer	−268K sh	—	—	0
2026-02-20	ANTXAN2 Therapeutics, Inc.A Award	Director, Chief Executive Officer	AAward	+112K sh	—	—	368,630
2026-02-20	ANTXAN2 Therapeutics, Inc. · Stock Option (right to buy)A Award	Director, Chief Executive Officer	AAward	+225K sh	—	—	224,500
2025-06-02	ANTXAN2 Therapeutics, Inc.P Purchase	Director, Chief Executive Officer	PPurchase	+10K sh	$1.07	+$10.7K	256,380
2025-02-26	ANTXAN2 Therapeutics, Inc.A Award	Director, Chief Executive Officer	AAward	+145K sh	—	—	246,380
2025-02-26	ANTXAN2 Therapeutics, Inc. · Stock Option (right to buy)A Award	Director, Chief Executive Officer	AAward	+291K sh	—	—	290,500
2024-11-18	ANTXAN2 Therapeutics, Inc.P Purchase	Director, Chief Executive Officer	PPurchase	+50K sh	$1.00	+$50K	1,065,766
2024-03-15	ANTXAN2 Therapeutics, Inc.A Award	Director, Chief Executive Officer	AAward	+99K sh	—	—	101,130
2024-03-15	ANTXAN2 Therapeutics, Inc.A Award	Director, Chief Executive Officer	AAward	+99K sh	—	—	101,130
2024-03-15	ANTXAN2 Therapeutics, Inc. · Stock Option (right to buy)A Award	Director, Chief Executive Officer	AAward	+198K sh	—	—	198,000
2024-01-02	ANTXAN2 Therapeutics, Inc.S Sale	Director, Chief Executive Officer	SSale	−2,777 sh	$20.09	−$55.8K	2,130
2023-05-15	ANTXAN2 Therapeutics, Inc.P Purchase	Director, Chief Executive Officer	PPurchase	+10K sh	$5.38	+$53.8K	1,015,766
2023-02-23	ANTXAN2 Therapeutics, Inc. · Stock Option (right to buy)A Award	Director, Chief Executive Officer	AAward	+268K sh	—	—	267,650
2022-11-14	ANTXAN2 Therapeutics, Inc.S Sale	Director, Chief Executive Officer	SSale	−23 sh	$15.04	−$345.92	4,907
2022-11-10	ANTXAN2 Therapeutics, Inc.S Sale	Director, Chief Executive Officer	SSale	−4,413 sh	$15.32	−$67.6K	4,930
2022-11-09	ANTXAN2 Therapeutics, Inc.S Sale	Director, Chief Executive Officer	SSale	−10.1K sh	$15.61	−$158K	4,907
2022-11-08	ANTXAN2 Therapeutics, Inc.S Sale	Director, Chief Executive Officer	SSale	−5,800 sh	$15.41	−$89.4K	16,273
2022-11-08	ANTXAN2 Therapeutics, Inc.S Sale	Director, Chief Executive Officer	SSale	−1,255 sh	$16.38	−$20.6K	15,018
2022-11-07	ANTXAN2 Therapeutics, Inc.S Sale	Director, Chief Executive Officer	SSale	−10.2K sh	$15.90	−$162K	6,943
2022-11-07	ANTXAN2 Therapeutics, Inc.S Sale	Director, Chief Executive Officer	SSale	−2,036 sh	$16.72	−$34K	4,907
2022-11-04	ANTXAN2 Therapeutics, Inc.S Sale	Director, Chief Executive Officer	SSale	−8,828 sh	$15.80	−$139K	17,110
2022-11-03	ANTXAN2 Therapeutics, Inc.S Sale	Director, Chief Executive Officer	SSale	−11.1K sh	$15.67	−$174K	29,021
2022-11-03	ANTXAN2 Therapeutics, Inc.S Sale	Director, Chief Executive Officer	SSale	−3,083 sh	$16.02	−$49.4K	25,938
2022-11-02	ANTXAN2 Therapeutics, Inc.S Sale	Director, Chief Executive Officer	SSale	−1,544 sh	$15.07	−$23.3K	4,907
2022-10-31	ANTXAN2 Therapeutics, Inc.S Sale	Director, Chief Executive Officer	SSale	−2,688 sh	$15.39	−$41.4K	6,451
2022-10-28	ANTXAN2 Therapeutics, Inc.S Sale	Director, Chief Executive Officer	SSale	−1,683 sh	$15.09	−$25.4K	4,907
2022-10-27	ANTXAN2 Therapeutics, Inc.S Sale	Director, Chief Executive Officer	SSale	−924 sh	$15.36	−$14.2K	6,590
2022-10-26	ANTXAN2 Therapeutics, Inc.S Sale	Director, Chief Executive Officer	SSale	−1,678 sh	$15.10	−$25.3K	4,907
2022-10-25	ANTXAN2 Therapeutics, Inc.S Sale	Director, Chief Executive Officer	SSale	−4,272 sh	$15.69	−$67K	7,119
2022-10-25	ANTXAN2 Therapeutics, Inc.S Sale	Director, Chief Executive Officer	SSale	−534 sh	$16.20	−$8,651.815	6,585
2022-10-24	ANTXAN2 Therapeutics, Inc.S Sale	Director, Chief Executive Officer	SSale	−2,866 sh	$16.17	−$46.3K	11,391
2022-10-21	ANTXAN2 Therapeutics, Inc.S Sale	Director, Chief Executive Officer	SSale	−11.6K sh	$16.29	−$189K	7,257
2022-10-21	ANTXAN2 Therapeutics, Inc.S Sale	Director, Chief Executive Officer	SSale	−2,350 sh	$16.69	−$39.2K	4,907
2022-10-20	ANTXAN2 Therapeutics, Inc.S Sale	Director, Chief Executive Officer	SSale	−7,262 sh	$16.68	−$121K	18,889
2022-10-20	ANTXAN2 Therapeutics, Inc.S Sale	Director, Chief Executive Officer	SSale	−31 sh	$17.15	−$531.501	18,858
2022-05-12	ANTXAN2 Therapeutics, Inc. · Stock Option (right to buy)A Award	Director, Chief Executive Officer	AAward	+225K sh	—	—	225,000
2022-03-29	ANTXAN2 Therapeutics, Inc.C Conversion	Director, Chief Executive Officer	CConversion	+4,907 sh	—	—	4,907
2022-03-29	ANTXAN2 Therapeutics, Inc. · Series A Convertible Preferred StockC Conversion	Director, Chief Executive Officer	CConversion	−4,907 sh	—	—	0

Recent filings

Accepted (ET)
Mar 234
Easom Eric0001193125-26-120192
SEC(opens sec.gov)
Feb 234
Easom Eric0001193125-26-064151
SEC(opens sec.gov)
Jun 34
Easom Eric0000950170-25-081041
SEC(opens sec.gov)
Feb 284
Easom Eric0000950170-25-030041
SEC(opens sec.gov)
Nov 184
Easom Eric0000950170-24-128202
SEC(opens sec.gov)
Mar 294/A
Easom Eric0001610717-24-000191
SEC(opens sec.gov)
Mar 184
Easom Eric0001610717-24-000164
SEC(opens sec.gov)
Jan 44
Easom Eric0001610717-24-000013
SEC(opens sec.gov)
May 154
Easom Eric0000899243-23-013012
SEC(opens sec.gov)
Feb 244
Easom Eric0000899243-23-006150
SEC(opens sec.gov)
Nov 144
Easom Eric0000899243-22-035782
SEC(opens sec.gov)

Companies

AN2 Therapeutics, Inc.Director, Chief Executive OfficerANTX

Address

C/O AN2 THERAPEUTICS, INC. 1300 EL CAMINO REAL, SUITE 100

MENLO PARK, CA, 94025